Tweets
♂♀ Does sex matter in #axSpA long-term?
GESPIC (n=525,10y):
Yes! ♂ less symptoms but 2x more spinal progression
#OP0101 #EULAR2026 @RheumNow https://t.co/znFXWyrfZl
Nelly ZIADE 🍀 @Nellziade ( View Tweet )
10 minutes 20 seconds ago
🔍 What defines a positive MRI for #axSpA?
SPARTAN-SSR consensus (n=1,050):
BME≥3 slices or 2/3 lesions in ≥3 SIJ quadrants
#OP0100 #EULAR2026 @RheumNow https://t.co/nfhzGxBZOm
Nelly ZIADE 🍀 @Nellziade ( View Tweet )
10 minutes 22 seconds ago
HLA-Cw6: a marker of more severe and difficult to manage psoriatic arthritis?
POS0484
#EULAR2026
@RheumNow https://t.co/MIYZxuYT4v
Nelly ZIADE 🍀 @Nellziade ( View Tweet )
10 minutes 25 seconds ago
Interesting pilot study using line-field confocal OCT for CLE
The “virtual biopsy” identified distinct layer-specific patterns across diff CLE subtypes including distinctions
bet ACLE & rosacea (dil. vessels, demodex mites, periannexal infil)
AbsOP099 @RheumNow #EULAR2026 https://t.co/yQSc6u4oYV
Links:
sheila @RHEUMarampa ( View Tweet )
10 minutes 27 seconds ago
Psoriatic arthritis #PsA sessions raised important topics on intercepting arthritis in psoriasis, treating obesity as a disease target, synovial biopsy to guide treatment, molecular imaging to reveal subclinical disease. More tomorrow. #Rheumatology @RheumNow #EULAR2026
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
10 minutes 29 seconds ago
Biopsy-guided treatment in PsA: match the drug to the tissue pathotype with 68% in LDA/remission vs 48% standard of care at 6 months. In myeloid CD117+ patients, mean DAPSA reduction at 6 months: IL-17i: −13.5, IL-23i: −12.8, TNFi: −7.5. Synovial biopsy with myeloid CD117+
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
58 minutes 36 seconds ago
It's unclear whether GLP-1agonists inmpvove PsA from weight loss or other MoA
74 PsA patients on GLP-1RA vs 74 matched controls (BMI + disease activity matched)
After adjusting for BMI change PROs still improve cDAPSA (-0.4/mo) DAPSA (-0.6/mo) and pain but not SJC, TJC or CRP https://t.co/dcaU2jwbKJ
Aurelie Najm @AurelieRheumo ( View Tweet )
58 minutes 40 seconds ago
Guselkumab gets FDA Nod for X-ray Protection
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's supplemental Biologics License (sBLA) to include evidence in the guselkumab (Tremfya) label for the inhibition of progression of structural joint damage in https://t.co/tlH7WM5gil
Dr. John Cush @RheumNow ( View Tweet )
1 hour 46 minutes ago
#OP0114 at #EULAR2026: Spanish study finds marked regional disparities in premature mortality from systemic connective tissue diseases. Higher socioeconomic deprivation and longer waits for specialist care were both linked to worse outcomes. @RheumNow https://t.co/04we2H0wdb
Mrinalini Dey @DrMiniDey ( View Tweet )
1 hour 50 minutes ago
ULT de-escalation in Gout: shall we do it?
Short answer: No
RCT 309 pts 24 mo
Primary outcome remission last 6 mo
79.2% ULT continuation vs 62.9% discontinuation p=0.002
Flare incidence 12% vs 32%
More NSAID/colchicine use after stopping ULT
Stopping ULT = urate rises quickly & https://t.co/bYKr5axu46
Aurelie Najm @AurelieRheumo ( View Tweet )
1 hour 50 minutes ago
❎HIGH Type 1 #interferon
=
Worse #scleroderma
In both
#limited #lcSSc
&
#diffuse #dcSSc
Leeds cohort
?biomarker
#EULAR2026 @RheumNow ABST#POS1092
ABST#POS0395 https://t.co/cRrBIpLgP9
Links:
Janet Pope @Janetbirdope ( View Tweet )
1 hour 50 minutes ago
#EULAR2026 OP0126 Long-term extension study up to 108 weeks: Ianalumab demonstrated sustained efficacy (change in ESSDAI) including those who switched from PBO to IAN in #Sjogren. IAN improved most domains apart from lungs, MSK & Haem - important to note @RheumNow #EULARBest https://t.co/x1d4G1s0jw
Links:
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
1 hour 50 minutes ago
